UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 2016
ENTELLUS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0001-36814 | 20-4627978 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3600 Holly Lane North, Suite 40
Plymouth, Minnesota 55447
(Address of principal executive offices) (Zip Code)
(763) 463-1595
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 9, 2016, Brian E. Farley, Executive Chairman of the Board of Directors (the “Board”) of Entellus Medical, Inc. (the “Company”), transitioned from Executive Chairman to non-executive Chairman of the Board. As non-executive Chairman of the Board, Mr. Farley will continue service as a director but will no longer be an employee of the Company. In connection with the transition, the Board amended Mr. Farley’s 2010 stock option such that the post-termination exercise period will be based off of his continued service with the Company, as opposed to his continued employment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENTELLUS MEDICAL, INC. | ||||||
| Date: January 11, 2016 |
||||||
| By: | /s/ Thomas E. Griffin | |||||
| Thomas E. Griffin | ||||||
| Chief Financial Officer | ||||||